Puerto Rico psoriasis study group

efficacy and safety of etanercept.

José R. González-Chavez, Alma C. Berlingeri-Ramos, Mary Ann Sánchez Casiano

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

BACKGROUND:Although major advances in the understanding of its pathogenesis have been achieved, psoriasis remains an incurable disease. In April 2004, etanercept, an antagonist of TNF-alpha, was approved by the Food and Drug Administration for the treatment of chronic, moderate to severe plaque psoriasis in adults. In this study we intend to document the efficacy and further establish the safety profile of etanercept for the treatment of moderate to severe psoriasis in our population and compare our data to the Leonardi et al study published in 2003. METHODS: A total of 26 patients were followed for a period of 24 weeks. Subjects were administered 25 mg of etanercept subcutaneously twice weekly for 24 weeks. Patients were seen every 4 weeks to measure clinical improvement by means of the psoriasis area and severity index (PASI) scores. Development of side effects was also assessed. RESULTS: Ninety-two percent of the patients had an improvement of greater than 50% in their PASI score, with 79% of these patients with a PASI improvement of 75% or greater. Adverse events were uncommon and none required the permanent discontinuation of treatment. CONCLUSION: Treatment with etanercept was well-tolerated and resulted in significant sustained improvement of psoriasis throughout a period of 24 weeks. Our data strongly correlates with the findings reported by Leonardi et al in 2003.

Original languageEnglish (US)
Pages (from-to)735-739
Number of pages5
JournalJournal of drugs in dermatology : JDD
Volume4
Issue number6
StatePublished - 2005

Fingerprint

Puerto Rico
Psoriasis
Safety
United States Food and Drug Administration
Therapeutics
Etanercept
Tumor Necrosis Factor-alpha
Population

Cite this

González-Chavez, J. R., Berlingeri-Ramos, A. C., & Sánchez Casiano, M. A. (2005). Puerto Rico psoriasis study group: efficacy and safety of etanercept. Journal of drugs in dermatology : JDD, 4(6), 735-739.

Puerto Rico psoriasis study group : efficacy and safety of etanercept. / González-Chavez, José R.; Berlingeri-Ramos, Alma C.; Sánchez Casiano, Mary Ann.

In: Journal of drugs in dermatology : JDD, Vol. 4, No. 6, 2005, p. 735-739.

Research output: Contribution to journalArticle

González-Chavez, JR, Berlingeri-Ramos, AC & Sánchez Casiano, MA 2005, 'Puerto Rico psoriasis study group: efficacy and safety of etanercept.', Journal of drugs in dermatology : JDD, vol. 4, no. 6, pp. 735-739.
González-Chavez JR, Berlingeri-Ramos AC, Sánchez Casiano MA. Puerto Rico psoriasis study group: efficacy and safety of etanercept. Journal of drugs in dermatology : JDD. 2005;4(6):735-739.
González-Chavez, José R. ; Berlingeri-Ramos, Alma C. ; Sánchez Casiano, Mary Ann. / Puerto Rico psoriasis study group : efficacy and safety of etanercept. In: Journal of drugs in dermatology : JDD. 2005 ; Vol. 4, No. 6. pp. 735-739.
@article{6833816667e441b29a6da96797a59a15,
title = "Puerto Rico psoriasis study group: efficacy and safety of etanercept.",
abstract = "BACKGROUND:Although major advances in the understanding of its pathogenesis have been achieved, psoriasis remains an incurable disease. In April 2004, etanercept, an antagonist of TNF-alpha, was approved by the Food and Drug Administration for the treatment of chronic, moderate to severe plaque psoriasis in adults. In this study we intend to document the efficacy and further establish the safety profile of etanercept for the treatment of moderate to severe psoriasis in our population and compare our data to the Leonardi et al study published in 2003. METHODS: A total of 26 patients were followed for a period of 24 weeks. Subjects were administered 25 mg of etanercept subcutaneously twice weekly for 24 weeks. Patients were seen every 4 weeks to measure clinical improvement by means of the psoriasis area and severity index (PASI) scores. Development of side effects was also assessed. RESULTS: Ninety-two percent of the patients had an improvement of greater than 50{\%} in their PASI score, with 79{\%} of these patients with a PASI improvement of 75{\%} or greater. Adverse events were uncommon and none required the permanent discontinuation of treatment. CONCLUSION: Treatment with etanercept was well-tolerated and resulted in significant sustained improvement of psoriasis throughout a period of 24 weeks. Our data strongly correlates with the findings reported by Leonardi et al in 2003.",
author = "Gonz{\'a}lez-Chavez, {Jos{\'e} R.} and Berlingeri-Ramos, {Alma C.} and {S{\'a}nchez Casiano}, {Mary Ann}",
year = "2005",
language = "English (US)",
volume = "4",
pages = "735--739",
journal = "Journal of Drugs in Dermatology",
issn = "1545-9616",
publisher = "Journal of Drugs in Dermatology",
number = "6",

}

TY - JOUR

T1 - Puerto Rico psoriasis study group

T2 - efficacy and safety of etanercept.

AU - González-Chavez, José R.

AU - Berlingeri-Ramos, Alma C.

AU - Sánchez Casiano, Mary Ann

PY - 2005

Y1 - 2005

N2 - BACKGROUND:Although major advances in the understanding of its pathogenesis have been achieved, psoriasis remains an incurable disease. In April 2004, etanercept, an antagonist of TNF-alpha, was approved by the Food and Drug Administration for the treatment of chronic, moderate to severe plaque psoriasis in adults. In this study we intend to document the efficacy and further establish the safety profile of etanercept for the treatment of moderate to severe psoriasis in our population and compare our data to the Leonardi et al study published in 2003. METHODS: A total of 26 patients were followed for a period of 24 weeks. Subjects were administered 25 mg of etanercept subcutaneously twice weekly for 24 weeks. Patients were seen every 4 weeks to measure clinical improvement by means of the psoriasis area and severity index (PASI) scores. Development of side effects was also assessed. RESULTS: Ninety-two percent of the patients had an improvement of greater than 50% in their PASI score, with 79% of these patients with a PASI improvement of 75% or greater. Adverse events were uncommon and none required the permanent discontinuation of treatment. CONCLUSION: Treatment with etanercept was well-tolerated and resulted in significant sustained improvement of psoriasis throughout a period of 24 weeks. Our data strongly correlates with the findings reported by Leonardi et al in 2003.

AB - BACKGROUND:Although major advances in the understanding of its pathogenesis have been achieved, psoriasis remains an incurable disease. In April 2004, etanercept, an antagonist of TNF-alpha, was approved by the Food and Drug Administration for the treatment of chronic, moderate to severe plaque psoriasis in adults. In this study we intend to document the efficacy and further establish the safety profile of etanercept for the treatment of moderate to severe psoriasis in our population and compare our data to the Leonardi et al study published in 2003. METHODS: A total of 26 patients were followed for a period of 24 weeks. Subjects were administered 25 mg of etanercept subcutaneously twice weekly for 24 weeks. Patients were seen every 4 weeks to measure clinical improvement by means of the psoriasis area and severity index (PASI) scores. Development of side effects was also assessed. RESULTS: Ninety-two percent of the patients had an improvement of greater than 50% in their PASI score, with 79% of these patients with a PASI improvement of 75% or greater. Adverse events were uncommon and none required the permanent discontinuation of treatment. CONCLUSION: Treatment with etanercept was well-tolerated and resulted in significant sustained improvement of psoriasis throughout a period of 24 weeks. Our data strongly correlates with the findings reported by Leonardi et al in 2003.

UR - http://www.scopus.com/inward/record.url?scp=33644681591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644681591&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 735

EP - 739

JO - Journal of Drugs in Dermatology

JF - Journal of Drugs in Dermatology

SN - 1545-9616

IS - 6

ER -